Evidence map›Paper›PMID 33801899›Full record

ReviewMolecules (Basel, Switzerland)2021

Anti-Tumor Drug Discovery Based on Natural Product β-Elemene: Anti-Tumor Mechanisms and Structural Modification.

Ziqiang Bai, Chuansheng Yao, Junlong Zhu, Yuanyuan Xie, Xiang-Yang Ye, Renren Bai, Tian Xie

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Exosome-like nanoparticles derived fromInternational journal of pharmaceutics: X · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. β-Elemene inhibits adipogenesis in 3T3-L1 cells by regulating AMPK pathway.Journal of clinical biochemistry and nutrition · 2025
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ziqiang BaiCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Chuansheng YaoCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Junlong ZhuCollege of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou 311121, China.
Yuanyuan XieCollege of Pharmaceutical Science, Zhejiang University of Technology, Hangzhou 310014, China.
Xiang-Yang YeCollege of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou 311121, China.
Renren BaiCollege of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou 311121, China.
Tian XieCollege of Pharmacy, School of Medicine, Hangzhou Normal University, Hangzhou 311121, China.
Hangzhou Normal University · CNZhejiang University of Technology · CN

Funding

Hangzhou Normal University School of Medicine Tearching Reform Fund 4125b30100112Hangzhou Normal University startup fund 4125C5021920419National Natural Science Foundation of China 81730108, 81973635 and 81803340Natural Science Foundation of Zhejiang Province LY20H300004
6 · The paper itself

Abstract

Natural products are important sources for drug discovery, especially anti-tumor drugs. β-Elemene, the prominent active ingredient extract from the rhizome of

Indexed as

Anticarcinogenic AgentsAntineoplastic AgentsAntineoplastic Agents, PhytogenicApoptosisBiological AvailabilityBiological ProductsCell Line, TumorChinaCurcumaHumansMonocyclic SesquiterpenesRhizomeSesquiterpenesSignal TransductionAnticarcinogenic AgentsAntineoplastic AgentsAntineoplastic Agents, Phytogenicbeta-elemeneBiological ProductsMonocyclic SesquiterpenesSesquiterpenesanti-tumormechanismnatural productstructural modificationβ-elemene

Identifiers

PMID33801899
PMCPMC7998186
OpenAlexW3134572475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.